Patents by Inventor Shelly Krebs

Shelly Krebs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES AGAINST CORONAVIRUSES AND USES THEREOF
    Publication number: 20240101645
    Abstract: The present disclosure is directed to monoclonal antibodies, or antigen-binding fragments thereof, that bind to coronavirus spike proteins, including the spike protein of SARS-CoV-2. These antibodies demonstrate high affinity binding to epitopes on the coronavirus spike protein and/or broad cross-reactivity to the spike protein of various coronaviruses. Compositions comprising the anti-coronavirus antibodies, nucleic acids encoding for the antibodies, recombinant expression vectors, and host cells are also disclosed. The present disclosure is also directed to methods of diagnosing, preventing or treating coronavirus infections, including infections or disease caused by SARS-CoV-2.
    Type: Application
    Filed: January 24, 2022
    Publication date: March 28, 2024
    Inventors: Shelly KREBS, Kayvon MODJARRAD, Nelson MICHAEL, Vincent DUSSUPT, Gina C. DONOFRIO, Samantha TOWNSLEY
  • Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
    Patent number: 11884718
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: January 30, 2024
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israeli Deaconess Medical Center, Inc., The Government Of The United States As Represented By The Secretary Of The Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson
  • Potent Zika Virus-Specific and Cross-Neutralizing Monoclonal Antibodies to Zika and Dengue Viruses Following Zikv Infection or Vaccination
    Publication number: 20210238262
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 5, 2021
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israel Deaconess Medical Center, Inc., The Government of the United States as Represented by the Secretary of the Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce